LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

Strona główna・Stock List・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Closed

Sector Healthcare

7.57 1.07

Buy Sell

Overview

Share price change

24h

Current

Min

7.39

Max

7.63

Key metrics
By Trading Economics
EPS	-0.172
Profit margin	-66.092
Employees	536

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+112.3 upside

Dividends
By Dow Jones
Next Earnings	31 paź 2024

Market Stats
By TradingEconomics
Market Cap	41M 990M
Previous open	6.5
Previous close	7.57

News Sentiment

By Acuity

21%

79%

43 / 366 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

6.1 / 7.65 Support & Resistance

BioCryst Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

16 paź 2024, 23:50 UTC

Hot Stocks

Stocks to Watch: Tesla, CSX, Alcoa

16 paź 2024, 23:30 UTC

Acquisitions, Mergers, Takeovers

Discover Financial, SEC Working to Resolve Misclassification Matter -- Update

16 paź 2024, 20:35 UTC

Earnings

CSX Posts Higher Revenue, Profit in 3Q on Increased Volume

16 paź 2024, 23:59 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

16 paź 2024, 23:59 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Woodside's LNG Deal Edges Ammonia Play, Bull Says -- Market Talk

16 paź 2024, 23:53 UTC

Market Talk

Gold Steady Ahead of Key U.S. Economic Data -- Market Talk

16 paź 2024, 23:50 UTC

Market Talk

Santos's Pikka Cost Rise Expected, But Builds Debt Pain -- Market Talk

16 paź 2024, 22:46 UTC

Top News

RTX Agrees to More Than $950 Million in Penalties to Settle Qatar Bribery, Contract Fraud Charges -- 2nd Update

16 paź 2024, 22:33 UTC

Top News

RTX Agrees to More Than $950 Million in Penalties to Settle Qatar Bribery, Contract Fraud Charges -- Update

16 paź 2024, 22:18 UTC

Top News

Elon Musk Taps Longtime Aide to Oversee Tesla's Operations in North America, Europe, Sources Say -- WSJ

16 paź 2024, 21:32 UTC

Earnings

Morgan Stanley's Bumper Earnings Power Stock to Record High -- Barrons.com

16 paź 2024, 21:20 UTC

Top News

China Security Group Urges Review of Intel's Chips as Tech Tension With U.S. Rises -- 2nd Update

16 paź 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16 paź 2024, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

16 paź 2024, 20:16 UTC

Top News

Dow Edges Up; Morgan Stanley Gains on Strong Earnings Headline -- WSJ

16 paź 2024, 20:12 UTC

Earnings

Kinder Morgan Cites Lower Than Budgeted Commodity Prices and Start-Up Delays on RNG Facilities >KMI

16 paź 2024, 20:11 UTC

Earnings

Kinder Morgan Expects Adj EBITDA to Be Up 5% and Adj EPS to Be Up 9% for FY Vs 2023 >KMI

16 paź 2024, 20:11 UTC

Earnings

Kinder Morgan Now Expects to Be Below Budget on Adj EBITDA by About 2% and on Adj EPS by About 4% >KMI

16 paź 2024, 20:10 UTC

Earnings

Kinder Morgan Expects to Declare Dividends of $1.15 Per Shr for 2024 >KMI

16 paź 2024, 20:10 UTC

Earnings

Kinder Morgan Budgeted 2024 DCF of $5 B, or $2.26 Per Share >KMI

16 paź 2024, 20:10 UTC

Earnings

Kinder Morgan Project Backlog at End of 3Q Was $5.1 B >KMI

16 paź 2024, 20:07 UTC

Earnings

Kinder Morgan: Final Investment Decision Reached for Gulf Coast Express Pipeline Expansion >KMI

16 paź 2024, 20:06 UTC

Earnings

CSX Corp: 4Q Volume Expected to Grow Modestly>CSX

16 paź 2024, 20:05 UTC

Earnings

CSX Corp: Lower revenue, Storm Impacts May Reduce Sequential Operating Margin in 4Q, Limiting 2H Margin Growth >CSX

16 paź 2024, 20:05 UTC

Earnings

Kinder Morgan 3Q Rev $3.7B >KMI

16 paź 2024, 20:05 UTC

Earnings

Kinder Morgan 3Q Adj EPS 25c >KMI

16 paź 2024, 20:05 UTC

Earnings

Kinder Morgan 3Q EPS 28c >KMI

16 paź 2024, 20:05 UTC

Earnings

Kinder Morgan 3Q Net $625M >KMI

16 paź 2024, 20:05 UTC

Earnings

Kinder Morgan Sees FY EPS $1.22 >KMI

16 paź 2024, 20:05 UTC

Earnings

Kinder Morgan Sees FY Net $2.7B >KMI

Peer Comparison

Price change

BioCryst Pharmaceuticals Inc Forecast

Price Target

By TipRanks

112.3% upside

12 Months Forecast

Average 15.88 USD 112.3%

High 30 USD

Low 7 USD

Based on 8 Wall Street analysts offering 12 month price targets forBioCryst Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to BioCryst Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

6.1 / 7.65Support & Resistance

Recent bullish events outweigh bearish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

43 / 366 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc. discovers oral and small-molecule medicines that treat rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The Company has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.